Simona Shaitelman, M.D., stood before a packed room at the European Society for Radiotherapy and Oncology (ESTRO 2026) Congress, not with a cautionary tale, but with a quiet revolution: 19 elderly women with early-stage breast cancer had gone three years without surgery—and without a single recurrence. At the heart of this breakthrough is a Phase 2 trial led by The University of Texas MD Anderson Cancer Center, challenging decades of surgical orthodoxy with a bold, non-operative approach combining endocrine therapy and ablative radiation.
For generations, surgery has been the cornerstone of breast cancer treatment. But now, with precision radiation and deeper understanding of tumor biology, a shift is emerging—one that honors patient choice, reduces physical burden, and redefines what remission can look like. This trial focused on a specific group: women with stage 1, hormone receptor-positive (HR+), HER2-negative breast cancers, all with favorable tumor profiles. With a median age of 71, these patients first received three months of endocrine therapy, which not only shrinks tumors but primes them for radiation. Then came the pivotal step: ablative radiation delivered in just five high-dose sessions, a far cry from the weeks-long regimens of the past.
The results were striking. Of the 19 patients who underwent post-treatment biopsies, 10—53%—showed a pathologic complete response, meaning no viable cancer cells were detected. More importantly, in those who opted to forgo surgery entirely, the tumor control rate remained 100% over a median follow-up of more than three years. No breast cancer-related deaths were reported. Researchers also identified three key predictors of success: smaller tumor size after hormone therapy, greater volume reduction before radiation, and higher estrogen receptor expression—clues that could help guide future patient selection.
This isn’t about eliminating surgery for all, but about expanding options for those who may benefit most. As Dr. Shaitelman emphasized, "Radiation therapy is widely accessible around the world, yet its full potential as a definitive treatment for breast cancer hasn't been fully explored." With over two million women diagnosed globally each year, the need for personalized, less invasive paths to healing has never been greater. The next step? A larger, multi-institutional trial to validate these findings and refine the criteria for non-operative care.
The vision is clear: a future where treatment is not one-size-fits-all, but shaped by biology, preference, and precision. For a growing number of patients, the scalpel may no longer be the only path to survival.